iCAD

What is iCAD?

iCAD develops AI for breast cancer detection through the ProFound Breast Health Suite. The company was acquired by RadNet in July 2025 and now operates as part of DeepHealth, RadNet's subsidiary.

Key capabilities of iCAD

• Cancer Detection: ProFound AI V3 for 2D and 3D mammography, FDA cleared, CE marked and Health Canada licensed
• Density Assessment: PowerLook Density Assessment gives objective breast density scoring
• Risk Evaluation: ProFound AI Risk is an image-based risk model, CE marked and Health Canada licensed, not FDA cleared
• Workflow integration: works with multiple mammography systems and PACS
• Flexible deployment: options for rapid implementation

How iCAD works

The software analyzes screening mammograms, 2D or 3D, to flag suspicious areas for the radiologist, scores breast density, and estimates risk from the image. Radiologists make the diagnosis. In the US, the Risk product is available for investigational use only.

Who uses iCAD?

Radiology practices and health systems running breast screening programs. Equipment partners include Hologic, Philips, Siemens, GE Healthcare, Canon and Fujifilm.

iCAD pricing

iCAD does not publish prices. Software is licensed through the vendor.

iCAD alternatives

Viz.ai and PathAI apply AI to other care and pathology workflows, while Iodine Software, SmarterDx and Adonis target hospital documentation and revenue cycle. iCAD is specific to breast imaging.